A Case of Fulminant Type 1 Diabetes Mellitus After the Administration of Durvalumab for Small-cell Lung Cancer

DOI Web Site 16 References
  • Terashi Naoki
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Hisakane Kakeru
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Miyadera Keiki
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Kato Yuki
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Terashima Yuto
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Suzuki Ayana
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Atsumi Kenichiro
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital
  • Seike Masahiro
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
  • Gemma Akihiko
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
  • Hirose Takashi
    Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital

Bibliographic Information

Other Title
  • デュルバルマブ投与後に劇症1型糖尿病を発症した小細胞肺癌の1例

Search this article

Abstract

<p>Background. Fulminant type 1 diabetes mellitus caused by immune checkpoint inhibitors is a rare adverse event. In lung cancer, several cases have been reported in non-small-cell lung cancer. We herein report a patient with small-cell lung cancer who developed fulminant type 1 diabetes mellitus after administration of durvalumab. Case. A 71-year-old man with extensive-stage small-cell lung cancer (cT4N3M1b, stage IVA) with no history of diabetes mellitus received combination therapy of carboplatin, etoposide, and durvalumab on May 20XX. He became aware of anorexia and fatigue on day 27. He was diagnosed with fulminant type 1 diabetes mellitus caused by durvalumab with hyperglycemia of 761 mg/dl, positive urine ketones, and urinary C-peptide of 3.9 μg/day on the second course of treatment (day 30). After his blood glucose level had been stabilized with insulin therapy, an additional three cycles of chemotherapy with carboplatin and etoposide were administered. A significant response was achieved, and the patient survived without disease progression. Conclusion. Fulminant type 1 diabetes mellitus caused by durvalumab for small-cell lung cancer is a rare but urgent immune-related adverse event that requires attention.</p>

Journal

  • Haigan

    Haigan 62 (4), 323-328, 2022-08-20

    The Japan Lung Cancer Society

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top